What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?

Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience

Gérald Raverot, Nathalie Stürm, Florence de Fraipont et al. · The Journal of Clinical Endocrinology & Metabolism · 2010 · 226 citations · Full text

Medicine, Oncology, Pharmacology +17

The role of germline <i>AIP</i>, <i>MEN1, PRKAR1A</i>, <i>CDKN1B</i> and <i>CDKN2C</i> mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes

MA Tichomirowa, Sosipatros A. Boikos, MF Azevedo et al. · Clinical Genetics · 2010 · 210 citations · Full text

Medicine, Endocrinology, Genetics +17

Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O⁶-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression

Zachary M. Bush, Janina A. Longtine, Tracy Cunningham et al. · The Journal of Clinical Endocrinology & Metabolism · 2010 · 152 citations · Full text

Medicine, Oncology, Pharmacology +17

Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings

Kálmán Kovács, Éva Horváth, Luis V. Syro et al. · Human Pathology · 2006 · 110 citations

Medicine, Endocrinology, Oncology +14

Pheochromocytoma in von Hippel-Lindau Disease: Distinct Histopathologic Phenotype Compared to Pheochromocytoma in Multiple Endocrine Neoplasia Type 2

Christian A. Koch, David Mauro, McClellan M. Walther et al. · Endocrine Pathology · 2002 · 89 citations

Medicine, Endocrinology, Oncology +16